The results for QRISK2 showed an improvement compared with the results of the original QRISK equation. 4 5 We disagree with the conclusion that 'using any of the models for initial systematic assessment of high or lower CVD [cardiovascular disease] risk would result in the majority of men and women to which the models apply getting very similar assessment and hence prioritisation for further investigation of treatment'. The key issue is the extent of reallocation. Allocation is critically dependent on the CVD risk score used and its performance in contemporaneous, ethnically diverse UK populations. The fact that ASSIGN, like Framingham, is associated with 20% or more overestimation in men results from a dependence on historical cohorts from the 1980s when the vascular epidemic was near its peak. Vascular mortality has halved in the succeeding decades and the incorrect allocation of individuals to high-risk categories will increase with the use of ASSIGN and Framingham.
The QRISK2 algorithm is derived from contemporaneous cohorts and is updated annually to take account of population trends in risk factors and disease incidence, improvements in data quality and changing requirements (eg, the need to incorporate a broader age range as in the GP 'QOF' Contract). QRISK2 (2010) has therefore been refitted to the latest version of the QResearch database and includes a broader age range of patients aged 30e84 years. 3 This has resulted in considerable improvements in performance as can be seen from table 1.
Systematic use of a cardiovascular risk score which does not include ethnicity is likely to underestimate risk, particularly in South Asians, and also contribute to widening health inequalities.
The inclusion of ethnicity is especially important given the effect of ethnicity on cardiovascular risk. For example, Pakistani men have a 97% increased risk of CVD compared with white men (adjusted HR 1.97, 95% CI 1.70 to 2.29). Using a 20% threshold to define high risk, 15% of South Asian men would be identified as high risk using QRISK2 (2010) compared with 10% using the NICE modified version of Framingham. Similarly, 8% of South Asian women would be identified as high risk using QRISK2 (2010) The Authors' reply Hippisley-Cox et al's response 1 to our paper published in this issue of Heart 2 highlights differences between QRISK 3 and QRISK2 4 asserting that QRISK2 improved on QRISK whereas an independent validation concluded that 'differences in performance were marginal'. 5 The wider CIs obtained in the independent validation of QRISK2 (y in table 1) by incorporating multiple imputation indicate little difference between the scores, once uncertainty is taken into account. 
